Remove Dosage Remove Drug Development Remove Packaging
article thumbnail

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Express Pharma

As environmental concerns continue to intensify, the pressure on the pharmaceutical industry to reduce its overall environmental impact, particularly in final dosage forms, is growing proportionately. Lonzas comprehensive sustainability approach spans the entire value chain, from raw material selection to end-of-life solutions.

Dosage 104
article thumbnail

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

Biopharmaceutics is a scientific discipline that examines the interrelationship of the physicochemical properties of the drug, the dosage form in which the drug is given, and the route of administration on the rate and extent of systemic drug absorption ( Applied Biopharmaceutics and Pharmacokinetics, Shargel, Wu-Pong and Yu, 5th Edition ).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Leading pharmaceutical solid dose (commercial dose) manufacturing companies in contract marketing

Pharmaceutical Technology

Pharmaceutical solid dosage forms are the most popular in the pharmaceutical industry and are one of the most used drug delivery methods across patient groups. Growth of oral solid dosage contract manufacturing in the pharmaceutical industry.

Dosage 40
article thumbnail

Unlocking the Potential: The Power of Drug Repurposing in Modern Medicine

Syner-G

By: Mayuri Mutha, Senior Manager, CMC Development & Project Management Joseph Sclafani PhD, Director, CMC Development & Project Management Drug development is a complex, expensive, and multistage process which could take 10 to 15 years to bring a new molecule from discovery to commercialization.

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.

article thumbnail

Patient Engagement in Pharma – Why and How?

Viseven

The traditional model of drug development and healthcare delivery is undergoing a seismic shift, with patient engagement emerging as a critical factor in achieving better health outcomes and driving innovation. This change is further driven by major regulatory bodies emphasizing Patient-Focused Drug Development (PFDD).

article thumbnail

Mitigating fill, finish and CCI challenges for injectables

Express Pharma

However, this philosophy isn’t just relegated to guiding the practices of medical professionals and drug developers. It extends all the way down to the healthcare sector’s expectations for every component, instrument, and process orbiting the development and manufacture of medicine—especially parenteral drugs.